Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis.
Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022 06; 149(6):2010-2020.e8.